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summary Herpes simplex virus type 2 (HSV2) infection is a major 
source of morbidity in human immunodeficiency virus (HIV)-infected 
patients, since reactivations – whether symptomatic or asymptomatic 
– are associated with increased HIV viral load and viral shedding. 
Acyclovir, valacyclovir and famcyclovir are indicated for the treatment 
of HSV2 in HIV patients. This class of drugs has been shown to 
enhance survival in HIV-infected individuals. However, with the 
emergence of drug-resistant strains of HSV2, the rates of resistance 
among HIV patients are almost ten-fold those in immunocompetent 
individuals, comparing 0.6% to 6%. These HSV2 infections tend to 
be more severe and to recur. More ominously, disease progression 
of HIV is promoted by concurrent infection with HSV2. Intravenous 
foscarnet and cidofovir may be used for acyclovir-resistant HSV; 
however, resistance to these drugs has been documented. Newer 
therapies such as the toll-like receptor agonist imiquimod and 
immunomodulating dipeptides offer promise for the treatment of 
HSV2 in HIV-infected individuals. 
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IntroduCtIon
Herpes simplex virus (HSV) infection is a ma-
jor cause of morbidity and even mortality in im-
munosuppressed individuals (1). Although both 
HSV1 and HSV2 infections occur more commonly 
among immunocompromised patients, HSV2 in-
fection has been more extensively studied in the 
human immunodeficiency virus (HIV)-infected 
population. HSV2 infection has been identified as 
a risk factor for HIV acquisition and transmission. 
HSV2 may accelerate HIV progression, increasing 
HIV viral shedding and viral loads in plasma and 
genital secretions (2-4). Although HSV2 antiviral 
therapy has been shown to reduce HIV replica-
tion, viral load and disease evolution, drug-resis-
tant HSV2 strains have begun to emerge. This 
review focuses on the natural history of HSV2 in-
fection in HIV-infected individuals, development of 
drug resistance in this population, and treatment 
options for drug-resistant HSV. 
HsV2/HIV synergy
epIdemIology 
The synergistic interaction between HSV2 and 
HIV infections is supported by epidemiological 
data (2,3,5-8,10,21). These studies demonstrate 
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that HSV2 predisposes individuals to HIV acqui-
sition and transmission, and accelerates HIV dis-
ease progression. HSV2 infection may be found in 
50%-90% of HIV-patients but only 22% of immu-
nocompromised patients (3-5). One study showed 
HSV2 to be associated with a two- to three-fold 
increase in the risk of HIV infection (5). A meta-
analysis of 18 longitudinal studies found the HSV2 
infection to be associated with an increased risk of 
HIV infection, with a relative risk of 3.1 in women, 
2.7 in heterosexual men and 1.7 in homosexual 
men (7). Mathematical modeling has projected 
that the peak incidence of HIV may double in the 
next ten years due to the presence of HSV2 (2). 
In co-infected individuals, acute HSV2 infec-
tions and reactivations may increase HIV repli-
cation and plasma viral load, with concomitantly 
increased genital HIV viral shedding and accel-
erated progression of HIV. Such HSV2 reactiva-
tions, more frequent and protracted in immuno-
suppressed individuals, may explain the greater 
transmissibility and faster disease progression in 
HIV-infected patients (6-8). 
patHogenesIs
Several biological mechanisms may explain 
the synergy between HSV2 and HIV, which are 
described below.  
disruption of mucosal integrity
HSV2 infection causes genital ulcerations, 
clinically obvious or microscopic (9). Disruptions 
to the epidermal barrier, as well as asymptomatic 
viral shedding, may trigger an immune response, 
resulting in the activation of CD4+ cells as well as 
the recruitment of dendritic cells expressing den-
dritic cell-specific intercellular adhesion molecule-
3-grabbing nonintegrin (7). Dendritic cells and 
CD4+ cells are targets easily infected by HIV.    
HsV2-induced immune activation
HSV2 infection increases HIV replication 
through immune mechanisms.  For example, T-
cell depletion by local and systemic immune acti-
vation may occur during acute HSV2 infection (8). 
HSV-mediated down-regulation of the cytokines 
interferon-γ and interleukin-12 has been shown to 
increase HIV replication. Also, HSV2 activation of 
host toll-like receptors has been linked to HIV pro-
gression (7). These various mechanisms all lead 
to more rapid disease progression by increasing 
HIV replication and depleting T cells, which further 
weakens the immune response.
HsV2 protein transactivation
ICP0, ICP27, ICP4, IE 110, and IE175 are im-
mediate-early HSV proteins, shown to increase 
HIV transcription in vitro (2). The interaction of 
ICP0, ICP27 and ICP4 with the HIV long terminal 
repeat (LTR) region induces the cellular activators 
nuclear factor kB (NF-kB) and Sp1. These acti-
vators ultimately up-regulate HIV replication (8). 
Also, these HSV proteins amplify HIV expression 
through post-transcriptional stabilization of HIV 
RNAs (2).
Disruption of vaginal flora
Bacterial vaginosis may play an intermedi-
ate role in the synergistic relationship of HIV and 
HSV2. HSV2 infection facilitates bacterial vagino-
sis. Normally, the lactic acid and hydrogen per-
oxide produced by vaginal lactobacilli maintain a 
low pH, which kills pathogens. Bacterial vaginosis 
causes a loss of the lactobacilli; the resulting loss 
of lactic acid and hydrogen peroxide increases 
vaginal pH, enabling the survival of HIV. Other ab-
normal bacterial flora of the vagina, such as Gar-
denella vaginalis, may recruit leukocytes and in-
crease pro-inflammatory cytokines, which, in turn, 
may activate the HIV LTR region and ultimately 
increase HIV replication (8).
ClInICal manIfestatIons of HIV 
and HsV2 Co-InfeCtIon
Immunosuppressed patients experience fre-
quent recurrences of HSV2 (1). These infections 
may be clinically atypical in appearance and lo-
cation; they may be extensive, deeply ulcerated 
or necrotic. Due to low CD4+ cell counts, recur-
rences tend to be protracted and poorly respon-
sive to therapy. The lesions may involve multiple 
sites and may have a longer duration of viral shed-
ding (1). 
Occasionally, HSV2 causes confluent verru-
cous papules and/or nodules on the penis, scro-
tum, vulva, intergluteal cleft, and other skin and 
mucosal areas, mimicking condyloma acumina-
tum, verrucous carcinoma, and other ulcerative 
diseases such as syphilis and chancroid (1,5). 
Rarely, esophagitis, encephalitis, hepatitis, pneu-
monitis or retinal necrosis may occur in systemic 
and disseminated disease (2,6). 
asymptomatic HsV2 reactivation
Most HSV2 reactivations are asymptomatic, 
with silent HIV viral shedding from mucosal sites. 
Such asymptomatic viral shedding correlates 
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inversely to the CD4+ cell counts and may occur 
in greater quantity and at a greater number of ana-
tomic sites in patients with lower CD4+ cell counts 
(<400 cell/mm3) (2). The rate of HSV2 shedding 
is highly correlated with plasma HIV RNA levels, 
and hence with more rapid disease progression 
(5). Highly active antiretroviral therapy (HAART) 
does not appear to alter the frequency of shedding 
or the titer of HSV2 shedding (3). 
antI-VIral HsV2 tHerapy and HIV 
Since its emergence in 1983, acyclovir has 
been the mainstay of therapy for HSV infections. 
Acyclovir is a nucleoside analog, and its mecha-
nism of action involves its phosphorylation by the 
HSV thymidine kinase (TK) to acyclovir mono-
phosphate. Cellular kinases further phosphorylate 
acyclovir monophosphate to acyclovir triphos-
phate (1,2,15). Since viral DNA polymerase has 
a higher affinity for acyclovir triphosphate than 
human cellular DNA polymerase, it may be incor-
porated into the growing viral DNA chain, result-
ing in chain termination and inhibition of viral DNA 
replication (2). 
Numerous studies have indicated that HSV an-
tiviral therapy enhances survival in HIV patients. 
Three randomized controlled trials have shown 
that treatment with oral valacyclovir decreases 
genital and plasma HIV replication (11-13). In 
another randomized trial, a greater than 0.5 log10 
copies/mL reduction in HIV blood viral load was 
observed after oral acyclovir therapy (14). A meta-
analysis of 8 randomized trials indicated that oral 
acyclovir offered a significant survival benefit for 
HIV-infected persons (hazard ratio, 0.78; 95% CI, 
0.65-0.93) (5). 
The exact mechanism by which antiviral HSV 
therapy enhances survival in HIV patients is un-
known but various mechanisms have been pro-
posed. Studies have suggested that HSV suppres-
sion may interfere with HIV up-regulation and may 
reduce HIV shedding in herpetic lesions within 
4-5 days of therapy initiation (5). Women treated 
with valacyclovir suppressive therapy had a mean 
of 0.35 log copies/mL cervicovaginal HIV levels 
lower than untreated females (11). Furthermore, a 
reduction in the recurrence of HSV ulcers and viral 
shedding may produce an overall beneficial effect 
on HIV progression (7).
drug resIstanCe In HIV patIents
Acyclovir resistance was first documented 
shortly after its emergence. In immunocompetent 
individuals, the prevalence of resistance is as high 
as 0.6%. By contrast, in immunocompromised indi-
viduals, the prevalence is almost ten times higher, 
ranging between 3% and 6% (15). A recent study 
indicated that 10% of HSV isolates obtained from 
AIDS-infected patients were resistant to acyclovir 
(16). Resistance to other classes of antivirals such 
as foscarnet has been documented as well. In a 
study of patients with excreted acyclovir-resistant 
HSV strains, 61% of those treated with foscarnet 
subsequently developed resistance to this drug 
(15). 
The generation of drug-resistant HSV strains 
may be attributed to the prolonged use of antivi-
ral medications in immunocompromised patients. 
The extended use of antiviral medications may 
lead to the selection of nucleoside analog-resis-
tant HIV strains resistant in 7%-14% of immuno-
compromised hosts (17). This can occur quickly, 
as resistant strains have been isolated as early 
as 17 hours after initiation of pencyclovir and two 
days after initiation with acyclovir (15). 
Host-related factors include the strength of the 
immune response mounted against HSV infection. 
In an immunocompromised individual, an attenu-
ated or negligible immune response against HSV2 
infection may result in the continuous replication 
of both wild type and resistant strains. The pro-
longed use of antiviral medications may further 
select mutant strains (18).
Drug-resistant HSV strains usually originate 
from mutations in thymidine kinase (TK) and DNA 
polymerase. Three types of acyclovir-resistant 
strains have been identified. These include 1) TK 
negative mutants that result from a deletion of the 
TK gene; 2) TK partial mutants that have reduced 
TK activity due to a mutation in the gene; and 
3) TK altered mutants that phosphorylate thymi-
dine but not acyclovir. Approximately 95% of acy-
clovir-resistant mutants lack TK activity or have 
reduced levels of the enzyme. Strains with muta-
tions in DNA polymerase and helicase-primase 
inhibitors are much less common (18,19). These 
mutations frequently arise spontaneously. Nota-
bly, in vitro acyclovir resistance may not correlate 
with clinical resistance (2). 
tHerapy
Acyclovir, valacyclovir and famcyclovir are in-
dicated for the treatment and suppression of both 
primary and recurrent HSV2 infections. Acyclovir-
resistant HSV2 isolates are usually not responsive 
to treatment with valacyclovir or famcyclovir due to 
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mutations in TK. In this case, therapy with a non 
TK-dependent drug, such as intravenous foscar-
net which targets viral DNA polymerase, may be 
initiated. Resistance to foscarnet on the basis of 
viral mutation has been documented. Intravenous 
cidofovir has been reported clinically effective for 
acyclovir- and foscarnet-resistant HSV2 strains 
(20). 
Imiquimod is a toll-like receptor (TLR) 7 ago-
nist, which targets both innate and cell-mediated 
pathways of the immune system. Imiquimod pro-
motes Th1 cell-mediated immune response (22), 
inhibits Th2 response (23), and induces functional 
maturation of Langerhans cells. This drug induc-
es lymphocytes to produce numerous cytokines 
such as interferon-α, known to have direct anti-
viral activity (21). This increased activation of the 
innate and cytotoxic-specific immune response is 
particularly helpful for immunocompromised pa-
tients (21). Resiquimod, an investigational analog 
of imiquimod with mixed TLR 7/8 activity, has had 
mixed success (22).  
Clinical reports on treatment of HSV-resistant 
infections with imiquimod describe rapid improve-
ment of skin lesions. In guinea pigs, topical imiqui-
mod is associated with a decrease in the number 
of primary lesions of HSV2 infections, a decrease 
in the number of episodes of viral shedding, and 
a reduction in viral load measured in the cerebro-
spinal fluid (23).
Helicase-primase inhibitors (HPIs) target the 
HSV helicase primase complex. This class of 
drugs is potent with low rates of resistance. It ap-
pears superior to nucleoside analogs in animal 
models. The use of HPIs in synergy with nucleo-
side analogs may delay the emergence of drug-
resistant strains (19,24). 
Distamycin A, a basic antibiotic belonging to 
the category of lexitropsin DNA minor groove bind-
ing drugs, has significant antiviral action against 
HSV2. Distamycin A inhibits activity of all DNA 
polymerases by forming a stable complex with 
double-stranded DNA (25).  
The immunomodulating dipeptide SCV-07 is 
another promising therapy for HSV2 infections. 
Guinea pigs infected genitally with HSV2 had sig-
nificantly reduced frequency and severity of recur-
rent disease when treated with SCV-07. Further 
investigation is needed (26). 
ConClusIon
The relationship between HSV2 infection and 
HIV is complex. HSV2 infection promotes HIV 
acquisition, transmission and disease progres-
sion by increasing viral loads and episodes of 
viral shedding. On the other hand, HIV infection 
increases the duration, severity and frequency of 
episodes of HSV2 reactivations. Although the ex-
act mechanisms of these synergistic interactions 
are unknown, numerous explanations have been 
proposed. Treatment of HSV2 infections with anti-
viral agents enhances survival for HIV patients by 
decreasing HIV replication, lowering viral loads, 
and reducing the number of episodes of viral 
shedding. 
It appears reasonable that HIV-positive indi-
viduals be evaluated for concurrent HSV2 infec-
tion and possibly be offered long-term suppres-
sive treatment. HSV2 resistance testing may be 
useful in patients with demonstrated clinical failure 
of HSV2 therapy to oral acyclovir, valacyclovir, or 
famcyclovir. Although intravenous foscarnet and 
cidofovir have been used successfully for resis-
tant strains, renal toxicity is a serious side effect 
of these drugs and therefore should be used with 
caution. Topical imiquimod may be of particular 
value, as it is clinically effective against resistance 
with HSV2 infection and has not been associated 
with any serious side effects. 
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